vs
HAWKINS INC（HWKN）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
HAWKINS INC的季度营收约是Ultragenyx Pharmaceutical Inc.的1.2倍（$244.1M vs $207.3M），HAWKINS INC净利率更高（5.9% vs -62.0%，领先67.9%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 7.9%），HAWKINS INC自由现金流更多（$21.2M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 8.2%）
霍金斯公司是印度知名厨具制造商，总部位于孟买，在塔那、霍希亚布尔、 jaunpur设有三座生产基地，旗下拥有Hawkins、Futura、Contura等多个品牌，主营压力锅及各类炊具产品，是印度规模最大的压力锅生产商之一，产品出口至全球超65个国家和地区。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
HWKN vs RARE — 直观对比
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $244.1M | $207.3M |
| 净利润 | $14.3M | $-128.6M |
| 毛利率 | 20.8% | — |
| 营业利润率 | 9.2% | -54.7% |
| 净利率 | 5.9% | -62.0% |
| 营收同比 | 7.9% | 25.9% |
| 净利润同比 | -4.7% | 3.5% |
| 每股收益（稀释后） | $0.69 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $244.1M | $207.3M | ||
| Q3 25 | $280.4M | $159.9M | ||
| Q2 25 | $293.3M | $166.5M | ||
| Q1 25 | $245.3M | $139.3M | ||
| Q4 24 | $226.2M | $164.6M | ||
| Q3 24 | $247.0M | $139.5M | ||
| Q2 24 | $255.9M | $147.0M | ||
| Q1 24 | — | $108.8M |
| Q4 25 | $14.3M | $-128.6M | ||
| Q3 25 | $22.6M | $-180.4M | ||
| Q2 25 | $29.2M | $-115.0M | ||
| Q1 25 | $16.3M | $-151.1M | ||
| Q4 24 | $15.0M | $-133.2M | ||
| Q3 24 | $24.1M | $-133.5M | ||
| Q2 24 | $28.9M | $-131.6M | ||
| Q1 24 | — | $-170.7M |
| Q4 25 | 20.8% | — | ||
| Q3 25 | 24.1% | — | ||
| Q2 25 | 24.7% | — | ||
| Q1 25 | 21.3% | — | ||
| Q4 24 | 21.4% | — | ||
| Q3 24 | 24.4% | — | ||
| Q2 24 | 25.3% | — | ||
| Q1 24 | — | — |
| Q4 25 | 9.2% | -54.7% | ||
| Q3 25 | 12.1% | -106.9% | ||
| Q2 25 | 14.1% | -64.8% | ||
| Q1 25 | 10.0% | -102.6% | ||
| Q4 24 | 9.3% | -74.3% | ||
| Q3 24 | 13.7% | -94.6% | ||
| Q2 24 | 15.6% | -79.1% | ||
| Q1 24 | — | -151.9% |
| Q4 25 | 5.9% | -62.0% | ||
| Q3 25 | 8.1% | -112.8% | ||
| Q2 25 | 9.9% | -69.0% | ||
| Q1 25 | 6.7% | -108.5% | ||
| Q4 24 | 6.6% | -80.9% | ||
| Q3 24 | 9.8% | -95.7% | ||
| Q2 24 | 11.3% | -89.5% | ||
| Q1 24 | — | -156.8% |
| Q4 25 | $0.69 | $-1.28 | ||
| Q3 25 | $1.08 | $-1.81 | ||
| Q2 25 | $1.40 | $-1.17 | ||
| Q1 25 | $0.77 | $-1.57 | ||
| Q4 24 | $0.72 | $-1.34 | ||
| Q3 24 | $1.16 | $-1.40 | ||
| Q2 24 | $1.38 | $-1.52 | ||
| Q1 24 | — | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $421.0M |
| 总债务越低越好 | $264.0M | — |
| 股东权益账面价值 | $518.9M | $-80.0M |
| 总资产 | $976.5M | $1.5B |
| 负债/权益比越低杠杆越低 | 0.51× | — |
8季度趋势，按日历期对齐
| Q4 25 | — | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | $5.1M | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M | ||
| Q1 24 | — | $112.3M |
| Q4 25 | $264.0M | — | ||
| Q3 25 | $279.0M | — | ||
| Q2 25 | $299.0M | — | ||
| Q1 25 | $149.0M | — | ||
| Q4 24 | $114.0M | — | ||
| Q3 24 | $104.0M | — | ||
| Q2 24 | $134.0M | — | ||
| Q1 24 | — | — |
| Q4 25 | $518.9M | $-80.0M | ||
| Q3 25 | $507.0M | $9.2M | ||
| Q2 25 | $484.6M | $151.3M | ||
| Q1 25 | $460.3M | $144.2M | ||
| Q4 24 | $457.0M | $255.0M | ||
| Q3 24 | $443.4M | $346.8M | ||
| Q2 24 | $421.2M | $432.4M | ||
| Q1 24 | — | $140.3M |
| Q4 25 | $976.5M | $1.5B | ||
| Q3 25 | $984.2M | $1.2B | ||
| Q2 25 | $988.3M | $1.3B | ||
| Q1 25 | $769.9M | $1.3B | ||
| Q4 24 | $707.2M | $1.5B | ||
| Q3 24 | $689.7M | $1.5B | ||
| Q2 24 | $702.7M | $1.6B | ||
| Q1 24 | — | $1.3B |
| Q4 25 | 0.51× | — | ||
| Q3 25 | 0.55× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | 0.32× | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.32× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $21.2M | $-100.8M |
| 自由现金流率自由现金流/营收 | 8.7% | -48.6% |
| 资本支出强度资本支出/营收 | 5.9% | 0.5% |
| 现金转化率经营现金流/净利润 | 2.48× | — |
| 过去12个月自由现金流最近4个季度 | $87.7M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $35.6M | $-99.8M | ||
| Q3 25 | $39.5M | $-91.4M | ||
| Q2 25 | $31.5M | $-108.3M | ||
| Q1 25 | $30.8M | $-166.5M | ||
| Q4 24 | $21.0M | $-79.3M | ||
| Q3 24 | $41.6M | $-67.0M | ||
| Q2 24 | $17.6M | $-77.0M | ||
| Q1 24 | — | $-190.7M |
| Q4 25 | $21.2M | $-100.8M | ||
| Q3 25 | $28.7M | $-92.7M | ||
| Q2 25 | $17.9M | $-110.7M | ||
| Q1 25 | $19.8M | $-167.8M | ||
| Q4 24 | $12.3M | $-79.5M | ||
| Q3 24 | $31.0M | $-68.6M | ||
| Q2 24 | $6.9M | $-79.0M | ||
| Q1 24 | — | $-193.9M |
| Q4 25 | 8.7% | -48.6% | ||
| Q3 25 | 10.2% | -58.0% | ||
| Q2 25 | 6.1% | -66.5% | ||
| Q1 25 | 8.1% | -120.5% | ||
| Q4 24 | 5.4% | -48.3% | ||
| Q3 24 | 12.5% | -49.2% | ||
| Q2 24 | 2.7% | -53.7% | ||
| Q1 24 | — | -178.2% |
| Q4 25 | 5.9% | 0.5% | ||
| Q3 25 | 3.9% | 0.8% | ||
| Q2 25 | 4.6% | 1.5% | ||
| Q1 25 | 4.5% | 1.0% | ||
| Q4 24 | 3.9% | 0.1% | ||
| Q3 24 | 4.3% | 1.2% | ||
| Q2 24 | 4.2% | 1.4% | ||
| Q1 24 | — | 3.0% |
| Q4 25 | 2.48× | — | ||
| Q3 25 | 1.75× | — | ||
| Q2 25 | 1.08× | — | ||
| Q1 25 | 1.89× | — | ||
| Q4 24 | 1.40× | — | ||
| Q3 24 | 1.73× | — | ||
| Q2 24 | 0.61× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HWKN
| Manufactured Blended Or Repackaged Products | $107.0M | 44% |
| Industrial Solutions | $53.6M | 22% |
| Food | $29.2M | 12% |
| Nutrition | $24.6M | 10% |
| Bulk Products | $12.0M | 5% |
| Water Surplus Inc. | $8.4M | 3% |
| Pharmaceutical | $7.3M | 3% |
| Other | $1.5M | 1% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
